<img height="1" width="1" style="display:none;" alt="" src="https://px.ads.linkedin.com/collect/?pid=384506&amp;fmt=gif">
Skip to content
    December 19, 2022

    Collaborative Drug Discovery Announces New NIH Grant to Develop Automated Molecular Identity Disambiguator

    CDD Press Release Logo

    The $1,119,880 supplemental grant from National Library of Medicine will allow CDD to develop Automated Molecular Identity Disambiguator (AutoMID)

    Burlingame, California - December 19, 2022 - Collaborative Drug Discovery, in collaboration with University of Miami, has received a $1,119,880 grant from National Library of Medicine to develop the Automated Molecular Identity Disambiguator (AutoMID).

    Small molecules are one of the most important classes of therapeutics alleviating suffering and in many cases death for hundreds of millions of people worldwide. Small molecules also serve as invaluable tools to study biology, often with the goal to validate novel targets for the development of future therapeutic drugs. Reproducibility of experimental results and the interoperability and reusability of resulting datasets depend on accurate descriptions of associated research objects, and most critically on correct representations of small molecules that are tested in biological assays. For example, it is not possible to develop predictive models of protein target - small molecule interactions if their chemical structure representations are not correct. Many factors contribute to errors in reported chemical structures in small molecule screening and omics reference databases, scientific publications, and many other web-based resources and documents. Because of the complexity of representing small molecules chemical structure graphs and the lack of thorough curation, errors are frequently introduced by non-experts and error propagation across different digital research assets is a pervasive problem. To address this challenging problem via a scalable approach, we propose the Automated Molecular Identity Disambiguator (AutoMID). AutoMID will be usable in batch mode at scale via an API, for example to assist chemical structure standardization and registration by maintainers of digital research assets, and also via interactive (UI) mode for everyday researchers to quickly and easily validate or correct their small molecule representations. AutoMID will leverage extensive highly standardized linked databases of chemical structures and associated information including names, synonyms, biological activity and physical properties and their sources / provenance and leverage expert rules and AI to enable reliable disambiguation of chemical structure identities at scale.

    About Collaborative Drug Discovery, Inc.

    CDD's (www.collaborativedrug.com) flagship product, "CDD Vault®", is used to manage chemical registration, structure-activity relationships (SAR), and securely scale collaborations. CDD Vault® is a hosted database solution for secure management and sharing of biological and chemical data. It lets you intuitively organize chemical structures and biological study data, and collaborate with internal or external partners through an easy to use web interface. Available modules within CDD Vault include Activity & Registration, Visualization, Inventory, and ELN.

    A complete list of more than 60 publications and patents from CDD can be found online on our resources page at https://www.collaborativedrug.com/publications-and-resources/.



    Media Contact: Barry Bunin, Ph.D., Collaborative Drug Discovery, marketing@collaborativedrug.com.

    Tag(s): CDD Blog , News

    Other posts you might be interested in

    View All Posts
    CDD Blog
    9 min   April 19, 2024
    Drug Discovery Industry Roundup with Barry Bunin — April 19, 2024
    Read More
    CDD Blog
    2 min   April 19, 2024
    CDD Appoints Yasushi Hamagashira as Head of Sales and Marketing for Japan
    Read More
    Events
    24 min   April 19, 2024
    Recap of CDD 20th Anniversary UGM – South San Francisco 2024
    Read More